CytoDyn, Inc. (OTC: CYDY)
Next Super Stock investor conference presentation 8/15/2019
CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation
Healthcare
CytoDyn (OTC: CYDY) Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV
VANCOUVER, Washington and NEW YORK, Dec 17, 2019 – In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone […]
Healthcare
CytoDyn (OTC: CYDY) Announces Productive Conference Call with FDA Regarding First BLA Submission for Leronlimab (PRO 140) Combination Therapy at 700 mg Dose
VANCOUVER, Washington, Feb 01, 2019 — Successful interim results in the 700 mg monotherapy arm prompted the FDA to allow CytoDyn to switch all remaining combination therapy patients from CD02-Extension study from 350 mg to […]
Healthcare
Impressive Results Continue from CytoDyn’s (OTC: CYDY) Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC
VANCOUVER, Washington, Jan 22, 2020 — First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab […]